A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine
Migraine headache is a widespread and complex neurobiological disorder that is characterized by unilateral headaches that are often accompanied by photophobia and phonophobia. Migraine is one of the leading chief complaints in the emergency department with negative impacts on quality of life and activities of daily living. The high number of emergency presentations also results in a significant economic burden. Its risk factors include family history, genetics, sex, race, socioeconomics, the existence of comorbid conditions, and level of education. Triggers include stress, light, noise, menstruation, weather, changes in sleep pattern, hunger, dehydration, dietary factors, odors, and alcohol. The International Headache Society has defined criteria for the diagnosis of migraine with and without aura. The pathophysiology of migraine headaches is multifactorial so there are a variety of treatment approaches. The current treatment approach includes abortive medications and prophylactic medications. Abortive medications include the first-line treatment of triptans, followed by ergot alkaloids, and calcitonin gene-related peptide (CGRP) receptor antagonists along with supplemental caffeine and antiemetics. Trigeminal afferents from the trigeminal ganglion innervate most cranial tissues and many areas of the head and face. These trigeminal afferents express certain biomarkers such as calcitonin gene-related peptide (CGRP), substance P, neurokinin A, and pituitary adenylate cyclase-activating polypeptide that are important to the pain and sensory aspect of migraines. In this comprehensive review, we discuss Zavegepant, a calcitonin gene-related peptide receptor antagonist, as a new abortive medication for migraine headaches.
1. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S.Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015
2. Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurology. 2013;12(5):454-461. doi:10.1016/s1474-4422(13)70067-x
3. Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1). doi:10.1186/s10194-019-1066-0
4. Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78(4):411-437. doi:10.1007/s40265-018-0865-y
5. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive Pharmacologic Treatments for Episodic Migraine in Adults. J Gen Intern Med. 2013;28(9):1225-1237. doi:10.1007/s11606-013-2433-1
6. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurology. 2010;9(3):285-298. doi:10.1016/s1474-4422(10)70005-3
7. Evans RW, Linde M. Expert Opinion: Adherence to Prophylactic Migraine Medication. Headache.2009;49(7):1054-1058. doi:10.1111/j.1526-4610.2009.01471.x
8. Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. J Neurosci. 2015;35(17):6619-6629. doi:10.1523/jneurosci.0373-15.2015
9. Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide Expression in the Human Trigeminal Nucleus Caudalis and in the Cervical Spinal Cord C1 and C2. Cephalalgia. 2002;22(2):112-116. doi:10.1046/j.1468-2982.2002.00324.x
10. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573-582. doi:10.1038/nrneurol.2010.127
11. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683-696. doi:10.1016/j.neuroscience.2010.05.016
12. Miller S, Liu H, Warfvinge K, et al. Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience. 2016;328:165-183. doi:10.1016/j.neuroscience.2016.04.046
13. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193-196. doi:10.1002/ana.410230214
14. Burch RC, Loder S, Loder E, Smitherman TA. The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies. Headache.2015;55(1):21-34. doi:10.1111/head.12482
15. Migraine Facts. Migraine Research Foundation.
16. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/s0140-6736(18)32279-7
17. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. doi:10.1212/01.wn1.0000252808.97649.21
18. Smitherman TA, Burch R, Sheikh H, Loder E. The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies. Headache. 2013;53(3):427-436. doi:10.1111/head.12074
19. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache. 2001;41(7):646-657. doi:10.1046/j.1526-4610.2001.041007646.x
20. Lipton RB, Bigal ME. Migraine: Epidemiology, Impact, and Risk Factors for Progression. Headache. 2005;45(s1):S3-S13. doi:10.1111/j.1526-4610.2005.4501001.x
21. Jiménez-Trujillo I, Lopez-de-Andrés A, del Barrio JL, Hernández-Barrera V, Valero-de-Bernabé M, Jiménez-Garcia R. Gender Differences in the Prevalence and Characteristics of Pain in Spain: Report from a Population-Based Study. Pain Med. 2019;20(12):2349-2359. doi:10.1093/pm/pnz004
22. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL III. Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings. J Pain. 2009;10(5):447-485. doi:10.1016/j.jpain.2008.12.001
23. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative Lifetime Migraine Incidence in Women and Men. Cephalalgia. 2008;28(11):1170-1178. doi:10.1111/j.1468-2982.2008.01666.x
24. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and Indirect Healthcare Resource and Men. Cephalalgia. 2018;58(5):700-714. doi:10.1111/head.13275
25. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837-850. doi:10.1177/0333102411398400
26. Mitsikostas DD, Thomas AM. Comorbidity of Headache and Depressive Disorders. Cephalalgia. 1999;19(4):211-217. doi:10.1046/j.1468-2982.1999.019004211.x
27. Buse DC, Scher AI, Dodick DW, et al. Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc. 2016;91(5):596-611. doi:10.1016/j.mayocp.2016.02.013
28. Tolner EA, Houben T, Terwindt GM, de Vries B, Ferrari MD, van den Maagdenberg AMJM. From migraine genes to mechanisms. Pain. 2015;156(Supplement 1):S64-S74. doi:10.1097/01.j.pain.0000460346.00213.16
29. Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. BMJ. 1995;311(7004):541-544. doi:10.1136/bmj.311.7004.541
30. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurology. 2017;16(1):76-87. doi:10.1016/s1474-4422(16)30293-9
31. Kruit MC. Migraine as a Risk Factor for Subclinical Brain Lesions. JAMA. 2004;291(4):427. doi:10.1001/jama.291.4.427
32. Scher IA, Stewart FW, Ricci AJ, Lipton BR. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1):81-89. doi:10.1016/s0304-3959(03)00293-8
33. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62(5):788-790. doi:10.1212/01.wnl.0000113747.18760.d2
34. Couch JR, Bearss C. Chronic Daily Headache in the Posttrauma Syndrome: Relation to Extent of Head Injury. Headache. 2001;41(6):559-564. doi:10.1046/j.1526-4610.2001.041006559.x
35. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5). doi:10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N
36. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. 2003 Wolff Award: Possible Parasympathetic Contributions to Peripheral and Central Sensitization During Migraine. Headache. 2003;43(7):704-714. doi:10.1046/j.1526-4610.2003.03127.x
37. Pavlovic JM, Buse DC, Sollars CM, Haut S, Lipton RB. Trigger Factors and Premonitory Features of Migraine Attacks: Summary of Studies. Headache. 2014;54(10):1670-1679. doi:10.1111/head.12468
38. Kelman L. The Triggers or Precipitants of the Acute Migraine Attack. Cephalalgia. 2007;27(5):394-402. doi:10.1111/j.1468-2982.2007.01303.x
39. Peroutka SJ. What Turns on a Migraine? A Systematic Review of Migraine Precipitating Factors. Curr Pain Headache Rep. 2014;18(10). doi:10.1007/s11916-014-0454-z
40. Borkum JM. Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis. Headache. 2016;56(1):12-35. doi:10.1111/head.12725
41. Headache Classification Committee of the International Headache Society(IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
42. Kelman L. The Premonitory Symptoms(Prodrome): A Tertiary Care Study of 893 Migraineurs. Headache. 2004;44(9):865-872. doi:10.1111/j.1526-4610.2004.04168.x
43. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The Prevalence of Premonitory Symptoms in Migraine: A Questionnaire Study in 461 Patients. Cephalalgia. 2006;26(10):1209-1213. doi:10.1111/j.1468-2982.2006.01195.x
44. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935-940. doi:10.1212/01.wnl.0000052998.58526.a9
45. Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain. 2015;16(1). doi:10.1186/s10194-015-0495-7
46. Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699-710. doi:10.1038/s41582-018-0098-4
47. Karsan N, Goadsby PJ. Imaging the Premonitory Phase of Migraine. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00140
48. Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurol Clin. 2019;37(4):707-725. doi:10.1016/j.ncl.2019.08.001
49. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. 2007;47(3):355-363. doi:10.1111/j.1526-4610.2006.00631.x
50. Viana M, Sances G, Terrazzino S, Sprenger T, Nappi G, Tassorelli C. When cervical pain is actually migraine: an observational study in 207 patients. Cephalalgia. 2018;38(2):383-388. doi:10.1177/0333102416683917
51. Goadsby PJ, Holland PR. Pathophysiology of Migraine. Neurol Clin. 2019;37(4):651-671. doi:10.1016/j.ncl.2019.07.008
52. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183-187. doi:10.1002/ana.410280213
53. van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2017;37(1):49-63. doi:10.1177/0333102415625614
54. May A. Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci. 2017;38(S1):125-130. doi:10.1007/s10072-017-2866-0
55. Gazerani P. Migraine and Diet. Nutrients. 2020;12(6):1658. doi:10.3390/nu12061658
56. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264(9):2031-2039. doi:10.1007/s00415-017-8434-y
57. Ceriani CEJ, Wilhour DA, Silberstein SD. Novel Medications for the Treatment of Migraine. Headache. 2019;59(9):1597-1608. doi:10.1111/head.13661
58. Rizzoli P. Preventive Pharmacotherapy in Migraine. Headache. 2014;54(2):364-369. doi:10.1111/head.12273
59. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive Pharmacologic Treatments for Episodic Migraine in Adults. J Gen Intern Med. 2013;28(9):1225-1237. doi:10.1007/s11606-013-2433-1
60. Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017;57(1):165-178. doi:10.1111/head.12997
61. Brown BL, Craycraft LK, Justice SB. Valproic Acid in the Treatment of Migraines. Adv Emerg Nurs J. 2020;42(4):243-253. doi:10.1097/tme.0000000000000319
62. Hosseinzadeh M, Khosravi A, Saki K, Ranjbar R. Evaluation of Helicobacter pylori infection in patients with common migraine headache. Arch Med Sci. 2011;5:844-849. doi:10.5114/aoms.2011.25560
63. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin Gene-Related Peptide: Physiology and Pathophysiology. Physiol Rev. 2014;94(4):1099-1142. doi:10.1152/physrev.00034.2013
64. Hargreaves R, Olesen J. Calcitonin Gene-Related Peptide Modulators- The History and Renaissance of a New Migraine Drug Class. Headache. 2019;59(6):951-970. doi:10.1111/head.13510
65. Huang D, Ren L, Qiu CS, et al. Characterization of a mouse model of headache. Pain. 2016;157(8):1744-1760. doi:10.1097/j.pain.0000000000000578
66. Hong P, Liu Y. Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis. Int J Neurosci. 2017;127(1):20-27. doi:10.3109/00207454.2015.1137915
67. Schytz HW, Olesen J. Laboratory tests of headache disorders- dawn of a new era? Cephalalgia. 2016;36(13):1268-1290. doi:10.1177/0333102415612585
68. Biohaven Pharmaceuticals. Zavegepnt.
69. Mercer SE, Chaturvedula PV, Conway CM, et al. Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett. 2021;31:127624. doi:10.1016/j.bmcl.2020.127624
70. Paemeliere K, MaassenVanDenBrink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol. 2018;31(3):274-280. doi:10.1097/wco.0000000000000548
71. Urits I, Jones MR, Gress K, et al. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. Curr Pain Headache Rep. 2019;23(5). doi:10.1007/s11916-019-0768-y
72. Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache. 2017;57:47-55. doi:10.1111/head.13081
73. Raffaelli B, Reuter U. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Neurotherapeutics. 2018;15(2):324-335. doi:10.1007/s13311-018-0622-7
74. Ha DK, Kim MJ, Han N, Kwak JH, Baek IH. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. Clin Drug Investig. 2021;41(2):119-132. doi:10.1007/s40261-020-00997-1
75. Chaturvedula PV, Mercer SE, Pin SS, et al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett. 2013;23(11):3157-3161. doi:10.1016/j.bmcl.2013.04.012
76. Pellesi L, Guerzoni S, Pini LA. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clin Pharmacol Drug Dev. 2017;6(6):534-547. doi:10.1002/cpdd.345
77. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019;19(12):1307-1317. doi:10.1080/14712598.2019.1671350
78. Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30(3):272-280. doi:10.1097/wco.0000000000000438
79. Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. J Med Chem. 2020;63(13):6600-6623. doi:10.1021/acs.jmedchem.9b01810
80. Presse release: Biohaven achieves positive topline results in pivotal phase 2/3 study of vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine. Biohaven Pharmaceuticals. Published 2019. Accessed July 16, 2021. https://www.biohavenpharmaceuticals.com/investors/news-events/press-releases/12-17-2019#:~:text=12%2F17%2F2019-,Biohaven%20Achieves%20Positive%20Topline%20Results%20in%20Pivotal%20Phase%202%2F3,unique%2C%20small%20molecule%20CGRP%20receptor
81. Moreno-Ajona D, Pérez-Rodriguez A, Goadsby PJ. Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med Drug Discov. 2020;7:100053. doi:10.1016/j.medidd.2020.100053
82. Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine. ClinicalTrials.gov. Published 2021. Accessed August 1, 2021. https://clinicaltrials.gov/ct2/show/record/NC T04408794
83. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001
84. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28(9):1225-1237. doi:10.1007/s11606-013-2433-1
85. Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366-373. doi:10.1177/0333102417736900
86. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019;59(S2):20-32. doi:10.1111/head.13583